Beijing Scitop Bio-tech Co., Ltd. (SHE:300858)

Market Cap	3.57B -22.6%
Revenue (ttm)	365.18M +3.9%
Net Income	54.04M -45.6%
EPS	0.21 -44.7%
Shares Out	263.50M
PE Ratio	64.42
Forward PE	n/a
Dividend	0.10 (0.74%)
Ex-Dividend Date	Jul 10, 2026

Volume	2,152,200
Open	13.00
Previous Close	13.35
Day's Range	13.00 - 13.63
52-Week Range	12.72 - 27.08
Beta	0.26
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Beijing Scitop Bio-tech

Beijing Scitop Bio-tech Co., Ltd. engages in the research, development, production, and sale of probiotic, postbiotics, and microecological preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women’s health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 413
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300858

Financial Performance

In 2025, Beijing Scitop Bio-tech's revenue was 365.92 million, an increase of 20.85% compared to the previous year's 302.79 million. Earnings were 94.52 million, an increase of 0.17%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 5, 2026

Data Sources Report a data error